Primary Immune Deficiency (PID) - Pipeline Insight, 2019

Primary Immune Deficiency (PID) - Pipeline Insight, 2019

  • February 2020 •
  • 106 pages •
  • Report ID: 5028217 •
  • Format: PDF
“Primary Immune Deficiency (PID) – Pipeline Insight, 2019” report outlays comprehensive insights of present scenario and growth prospects across Primary Immune Deficiency (PID). A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type.

Products covered by Phase
• Phase III, Phase II, Phase I
• Pre-clinical & Discovery
• Inactive (Discontinued and Dormant)

Overview of pipeline development activities for Primary Immune Deficiency (PID)
Pipeline analysis of therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and pre-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.

Therapeutic segmentation of products for Primary Immune Deficiency (PID)
The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this indication.

Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by a team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope of the report
• Provides an overview of therapeutic pipeline activity for Primary Immune Deficiency (PID) across the complete product development cycle including all clinical and non-clinical stages
• It comprises of detailed profiles of Primary Immune Deficiency (PID) therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, designations, technologies and chemical information
• Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
• Coverage of dormant and discontinued pipeline projects across Primary Immune Deficiency (PID)

Reasons to Buy
• Establish a comprehensive understanding of the current pipeline scenario across Primary Immune Deficiency (PID) to formulate effective R&D strategies
• Assess challenges and opportunities that influence Primary Immune Deficiency (PID) R&D
• Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Identify the relationship between the product and use it for target finding, drug repurposing, and precision medicine
• Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Primary Immune Deficiency (PID) to enhance and expand business potential and scope
• Our extensive domain knowledge on therapy areas support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs